

32801

PATENT TRADEMARK OFFICE

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/695,446		
		Filing Date	October 24, 2000		
		First Named Inventor	Suzana Petanceska		
		Art Unit	1615		
		Examiner Name	Liliana Di Nola Baron		
Sheet	1	of	2	Attorney Docket Number	00630/100G184-US1


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
lu	1.	Sally A. Shumaker, PhD et al., "Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women" American Medical Assoc., Jama, Vol.291, No.24, pgs. 2947-2958, 2004	
	2.	Mark A. Espeland, PhD et al., "Conjugated Equine Estrogens and Global Cognitive Function in Postmenopausal Women" American Medical Assoc., Jama, Vol. 291, No. 24, pgs. 2959-2968, 2004	
	3.	V.W. Henderson, MD et al. "Estrogen for Alzheimer's disease in women" American Academy of Neurology, pgs. 295-301, Vol. 54, January 2000	
	4.	Ruth A. Mulnard, et al., "Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease" American Medical Assoc., Jama, Vol. 283, No.283, Nos. 8, 20 pgs.1007-2597, 2000	
	5.	Peter R. Rapp, et al., "Cyclic Estrogen Replacement Improves Cognitive Function in Aged Ovariectomized Rhesus Monkeys", The Journal of Neuroscience (2003), Vol. 23 pgs. 5708-5714	
	6.	Justine A. Levin-Allerhand, et. al., "17 α -estradiol and 17 β -estradiol treatments are effective in lowering cerebral amyloid- β levels in A β PPSWE transgenic mice, Journal of Alzheimer's Disease 4 (2002) pgs. 449-457	
	7.	T. Heikkinen et al., "Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation", Experimental Neurology, Vol. 187 (2004) pgs. 105-117	
	8.	Peter P. Zandi, PhD et al., "Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women" American Medical Assoc (2002), Jama, Vol. 288, No. 17, pgs.2123-2129	

(W:1006 30/100)	lu	Date Considered	12/04
--------------------	----	--------------------	-------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/695,446
Filing Date	October 24, 2000
First Named Inventor	Suzana Petanceska
Art Unit	1615
Examiner Name	Liliana Di Nola Baron
Attorney Docket Number	00630/100G184-US1

Sheet	2	of	2
-------	---	----	---

9.	Susan M. Resnick, PhD et al., "Hormone Therapy and Risk of Alzheimer Disease" American Medical Assoc. (2002), Jama, Vol. 288, No. 17, pgs. 2170-2172	
10.	Mark A. Smith, Ph.D. et al, "Estrogen Replacement and Risk of Alzheimer Disease", American Medical Assoc. (2003), Jama, Vol. 289, No. 9, pgs 1100-1102	
11.	E. M. Johnstone et al., "Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis" (1991) Molec. Brain Rsh., Vol. 10, pgs 299-305.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

W:1006 30/100	Kush	Date Considered	12/04
------------------	------	--------------------	-------